Conference Coverage

VIDEO: Inflammation’s role in atherosclerosis confirmed in CANTOS


 

AT THE ESC CONGRESS 2017

– The results of the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) mark the validation of many years of research on inflammation for Peter Libby, MD, Mallinckrodt Professor of Medicine, Harvard Medical School, Boston.

The CANTOS investigator said that, although some trials, most notably JUPITER, have linked reduced markers of inflammation with reduced cardiovascular events, none have been able to separate the effects of lowering LDL cholesterol from those of lowering the inflammatory marker interleukin-1B.

But using the monoclonal antibody canakinumab to target only interleukin-1B in CANTOS reduced the composite endpoint of nonfatal MI, nonfatal stroke, or cardiovascular death by 15% at the highest dosage tested, compared with placebo, while lowering high-sensitivity C-reactive protein by 39 percentage points.

Dr. Libby has been studying interleukin-1B since the 1980s. “Now, today, for the first time, in a rigorous trial, we can show that an anti-inflammatory agent that is neutral for lipids (that doesn’t lower LDL) can provide a benefit for our patients, and that’s a real step forward,” Dr. Libby said in a video interview at the annual congress of the European Society of Cardiology.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

Importantly, a dividend of the investigation was that “we found a decrease in fatal cancers, particularly lung cancer. So this again opens the door toward a whole new therapeutic window in patients not just in the cardiovascular space, but also in oncology. So it’s a doubly exciting day for us.”

CANTOS was presented at the meeting by Paul Ridker, MD, also of Harvard Medical School; the results were also published online (N Engl J Med. 2017 Aug 27. doi: 10.1056/NEJMoa1707914).

Recommended Reading

Statins, but not aspirin, linked to lower pancreatic cancer risk
MDedge Hematology and Oncology
Overweight, obesity increase risk of cardiotoxicity from anthracyclines
MDedge Hematology and Oncology
Study shows faster increase in obesity prevalence among cancer survivors
MDedge Hematology and Oncology
Lipid-lowering meds benefit some breast cancer patients
MDedge Hematology and Oncology
Testosterone Trials’ cardiac, cognitive results disappoint
MDedge Hematology and Oncology
Death watch intensifies for HDL-based interventions
MDedge Hematology and Oncology
Game over: VTE is a risk in obese, sedentary teens
MDedge Hematology and Oncology
Herpes zoster raises risk of stroke, MI
MDedge Hematology and Oncology
Stopping statins after stroke may up recurrent stroke risk
MDedge Hematology and Oncology
Fat shaming interferes with patients’ medical care, experts say
MDedge Hematology and Oncology